Tumour Microenvironment conference
| Dates: | 5 June 2014 - 6 June 2014 |
|---|
| Times: | All day |
|---|
| What is it: | Conferences |
|---|
| Organiser: | Institute of Cancer Sciences |
|---|
| Who is it for: | Adults |
|---|
| Speaker: | Michael Lisanti, Salvador Moncada, Judith Campisi, Peter Carmeliet, Adrian Harris, Mien-Chie Hung, Guido Kroemer, Ubaldo Martinez, Timothy McGraw, Arne Ostman, Thea Tlsty , Melissa Troester |
|---|
|
Host: Institute of Cancer Sciences
Chair: Professor Michael Lisanti will be chairing this international conference.
About the event:
Topics covered include:
- Tumor-Stromal Interactions
- The Reverse Warburg Effect and Metabolic-Symbiosis
- Metabolic Reprogramming
- Tumor Microenvironment, Hypoxia, Malignant Progression, and Metastasis
- Cancer Associated Fibroblasts (CAFs) and Cancer Stem Cells
The concept that tumor-host interactions are crucial in tumor progression is now well-accepted. In fact, the English Surgeron Stephen Paget first proposed the “seed and soil” hypothesis in 1889, which states that cancer cells (“the seeds”) metastasize systemically and grow best in the most tumor-promoting host organs or the most “fertile soil.”
In this context, tumor cells corrupt or transform their microenvironment in order to generate new blood vessels to support their oxygen requirements. Closely linked to this idea, we and others have begun to view cancer as a “parasitic disease” that “steals” energy-rich metabolites from the host microenvironment.
The tumor stroma, which is composed of fibroblasts, adipocytes, endothelial cells and macrophages, lies in extremely close proximity to cancer cells, and can directly promote tumor growth. Recent studies indicated that the tumor microenvironment can help determine clinical outcome in human cancer patients and may also confer drug-resistance and treatment failure, leading to tumor recurrence and metastasis.
Thus, a better understanding of the tumor microenvironment is required for us to achieve the goals of personalized medicine, with more effective individualized patient based diagnostics and therapeutics.
Additional topics to be covered:
- The Epithelial-Mesenchymal Transition (EMT)
- Drug Resistance and Tumor Dormancy
- Escape Mechanism(s) During Anti-Angiogenic Therapy
- Designing Better Pre-Clinical Models
- Prognostic Stromal Biomarkers
- Personalized Medicine and Patient Treatment Stratification
Registration:
Please register through Abcam to attend this event. Prices can also be found on the registration page.
Speakers
Michael Lisanti
Role: Director of the Manchester Breakthrough Breast Cancer Research Unit
Organisation: University of Manchester, UK
Salvador Moncada
Role: Institute Director of Cancer Sciences
Organisation: University of Manchester, UK
Judith Campisi
Organisation: Buck Institute for Research on Aging, US
Peter Carmeliet
Organisation: VIB, Belgium
Adrian Harris
Organisation: Weatherall Institute of Molecular Medicine, UK
Mien-Chie Hung
Organisation: University of Texas MD Anderson Cancer Center, US
Guido Kroemer
Organisation: INSERM, France
Ubaldo Martinez
Organisation: Jefferson University Hospital, US
Timothy McGraw
Organisation: Weill Medical College of Cornell University, US
Arne Ostman
Organisation: Karolinska Institutet, Sweden
Thea Tlsty
Organisation: UCSF, US
Melissa Troester
Organisation: UNC Lineberger Comprehensive Cancer Center, US
Travel and Contact Information
Find event
Harvard University Joseph B. Martin Conference Center
Medical Center Area
Boston,
USA
